journal
MENU ▼
Read by QxMD icon Read
search

Thrombosis and Haemostasis

journal
https://www.readbyqxmd.com/read/28331932/pulmonary-embolism-and-in-situ-pulmonary-artery-thrombosis-in-paediatrics-a-systematic-review
#1
Madhvi Rajpurkar, Tina Biss, Ernest Amankwah, Denise Martinez, Suzan Williams, C Heleen Van Ommen, Neil A Goldenberg
Data on paediatric pulmonary embolism (PE) are scarce. We sought to systematically review the current literature on childhood PE and conducted a search on paediatric PE via PubMed (1946-2013) and Embase (1980-2013). There was significant heterogeneity in reported data. Two patterns were noted: classic thromboembolic PE (TE-PE) and in situ pulmonary artery thrombosis (ISPAT). Mean age of presentation for TE-PE was 14.86 years, and 51 % of cases were males. The commonest method for diagnosis of TE-PE was contrast CT with angiography (74 % of patients)...
March 23, 2017: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/28331929/confirmation-of-longer-fix-activity-half-life-with-prolonged-sample-collection-after-single-doses-of-nonacog-alfa-in-patients-with-haemophilia-b
#2
Baolai Hua, Runhui Wu, FeiFei Sun, Binyu Luo, Christine Alvey, Robert Labadie, Peng Roger Qu, Joan M Korth-Bradley, Pablo Rendo
A multicentre, single-dose study enrolled 12 previously treated patients with moderately severe to severe (factor IX [FIX] levels ≤2 IU/dl) haemophilia B to assess FIX pharmacokinetics after nonacog alfa administration and to evaluate the impact of length of sampling time on half-life (t½). After refraining from FIX replacement for four days, patients received 50 IU/kg as an intravenous (IV) infusion over 10 minutes. Blood samples were collected predose and 0.25, 0.5, 1, 3, 6, 9, 24, 50, 72, and 96 h post dose...
March 23, 2017: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/28331926/cessation-of-oral-anticoagulation-is-an-important-risk-factor-for-stroke-and-mortality-in-atrial-fibrillation-patients
#3
José Miguel Rivera-Caravaca, Vanessa Roldán, María Asunción Esteve-Pastor, Mariano Valdés, Vicente Vicente, Gregory Y H Lip, Francisco Marín
Oral anticoagulation (OAC) is highly effective preventing stroke and mortality in AF, but withdrawal is common in the elderly, when high bleeding risk and when are difficulties achieving an optimal time in therapeutic range (TTR). We analysed the rate of OAC cessation, predisposing factors to cessation and the relation to clinical outcomes in a large 'real world' cohort of AF patients over a long follow-up period. Consecutive non-valvular AF outpatients clinically stables for six months were recruited. Rates of cardiovascular events, major bleeding and mortality were recorded and related to OAC cessation...
March 23, 2017: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/28331925/biological-effects-of-ticagrelor-over-clopidogrel-in-patients-with-stable-coronary-artery-disease-and-chronic-obstructive-pulmonary-disease
#4
Gianluca Campo, Francesco Vieceli Dalla Sega, Rita Pavasini, Giorgio Aquila, Francesco Gallo, Francesca Fortini, Elisabetta Tonet, Paolo Cimaglia, Annamaria Del Franco, Gabriele Pestelli, Alessandro Pecoraro, Marco Contoli, Cristina Balla, Simone Biscaglia, Paola Rizzo, Roberto Ferrari
Patients with SCAD and concomitant COPD are at high risk of cardiovascular adverse events, due to chronic inflammation, responsible of endothelial dysfunction, oxidative stress and heightened platelet reactivity (PR). The objective of this randomised clinical trial was to test if ticagrelor is superior to clopidogrel in improving endothelial function in patients with stable coronary artery disease (SCAD) and concomitant chronic obstructive pulmonary disease (COPD). Forty-six patients with SCAD and COPD undergoing percutaneous coronary intervention (PCI) were randomly assigned to receive clopidogrel (n=23) or ticagrelor (n=23) on top of standard therapy with aspirin...
March 23, 2017: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/28331924/mortality-and-cancer-risk-on-long-term-antiplatelet-treatment-what-is-known-and-what-we-still-don-t-know
#5
Dirk Sibbing, Dániel Aradi
No abstract text is available yet for this article.
March 23, 2017: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/28331923/oral-trans-mucosal-administration-of-ticagrelor-is-this-really-the-future
#6
Fabiana Rollini, Francesco Franchi, Dominick J Angiolillo
No abstract text is available yet for this article.
March 23, 2017: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/28300870/effectiveness-and-safety-of-apixaban-versus-warfarin-in-non-valvular-atrial-fibrillation-patients-in-real-world-clinical-practice-a-propensity-matched-analysis-of-76-940-patients
#7
Xiaoyan Li, Steve Deitelzweig, Allison Keshishian, Melissa Hamilton, Ruslan Horblyuk, Kiran Gupta, Xuemei Luo, Jack Mardekian, Keith Friend, Anagha Nadkarni, Xianying Pan, Gregory Y H Lip
The ARISTOTLE trial showed a risk reduction of stroke/systemic embolism (SE) and major bleeding in non-valvular atrial fibrillation (NVAF) patients treated with apixaban compared to warfarin. This retrospective study used four large US claims databases (MarketScan, PharMetrics, Optum, and Humana) of NVAF patients newly initiating apixaban or warfarin from January 1, 2013 to September 30, 2015. After 1:1 warfarin-apixaban propensity score matching (PSM) within each database, the resulting patient records were pooled...
March 16, 2017: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/28300869/e-selectin-inhibition-with-gmi-1271-decreases-venous-thrombosis-without-profoundly-affecting-tail-vein-bleeding-in-a-mouse-model
#8
Dorian L Culmer, Misha L Dunbar, Angela E Hawley, Suman Sood, Robert E Sigler, Peter K Henke, Thomas W Wakefield, John L Magnani, Daniel D Myers
Selectins, such as E-selectin (CD62E), function in venous thrombosis by binding and activating immune cells to initiate the coagulation cascade. GMI-1271 is a small molecule antagonist that inhibits E-selectin activity. Here we determine whether inhibition of E-selectin is sufficient to decrease acute venous thrombosis and associated inflammatory events in both prophylactic and treatment protocols without significantly affecting haemostasis. Male C57BL/6 mice underwent surgery for experimental thrombosis induction and were harvested at peak thrombus formation in our animal model, two days post induction...
March 16, 2017: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/28300868/control-of-anticoagulation-with-vkas-overestimation-of-median-ttr-when-assessed-by-linear-interpolation-reply
#9
Joseph S Biedermann, Antonius M H P van den Besselaar, Felix J M van der Meer, Henk J Adriaansen, Frank W G Leebeek, Marieke J H A Kruip
No abstract text is available yet for this article.
March 16, 2017: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/28300867/consistent-platelet-inhibition-with-ticagrelor-60-mg-twice-daily-following-myocardial-infarction-regardless-of-diabetes-status
#10
Mark R Thomas, Dominick J Angiolillo, Marc P Bonaca, Ramzi A Ajjan, Heather M Judge, Fabiana Rollini, Francesco Franchi, Arif J Ahsan, Deepak L Bhatt, Julia F Kuder, Philippe Gabriel Steg, Marc Cohen, Rangasamy Muthusamy, Marc S Sabatine, Robert F Storey
Diabetes increases cardiovascular risk and reduces pharmacodynamic response to some oral antiplatelet drugs. This study aimed to determine whether ticagrelor 60 mg twice daily (bid) provided potent and consistent platelet inhibition in patients with vs without diabetes in the PEGASUS-TIMI 54 platelet function substudy. Out of 180 patients studied, 58 patients were randomised to and had received at least four weeks of ticagrelor 60 mg bid, with 20 (34 %) having diabetes, 58 patients received ticagrelor 90 mg bid, with 12 (21 %) having diabetes, and 64 patients received placebo, with 18 (28 %) having diabetes...
March 16, 2017: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/28300866/thrombotic-risk-according-to-serpinc1-genotype-in-a-large-cohort-of-subjects-with-antithrombin-inherited-deficiency
#11
Martine Alhenc-Gelas, Genevieve Plu-Bureau, Justine Hugon-Rodin, Véronique Picard, Marie-Helene Horellou
Inherited quantitative (type I) or qualitative (type II) antithrombin deficiency (ATD) due to mutations in the SERPINC1 gene is a well-known risk factor for venous thromboembolism. ATD may also increase risk for arterial thrombosis. Few studies have investigated risk for thrombosis according to mutations. We addressed this topic in a large retrospective cohort study of 540 heterozygous carriers of SERPINC1 mutations and compared risk for first venous or arterial thrombosis associated with carrying of different type II or type I mutations...
March 16, 2017: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/28300865/comparative-safety-and-effectiveness-of-rivaroxaban-versus-vkas-in-patients-with-venous-thromboembolism-a-danish-nationwide-registry-based-study
#12
Caroline Sindet-Pedersen, Jannik Langtved Pallisgaard, Laila Staerk, Thomas Alexander Gerds, Emil Loldrup Fosbøl, Christian Torp-Pedersen, Gunnar Gislason, Jonas Bjerring Olesen
The approval of rivaroxaban has changed the landscape of treatment of venous thromboembolism (VTE). Little is known about the effect of rivaroxaban compared with vitamin K antagonists (VKA), when used in the everyday clinical practice. The aim of this study was to investigate the safety and effectiveness of rivaroxaban compared with VKAs among patients with VTE, using the Danish nationwide registries. All patients diagnosed with VTE and treated with either rivaroxaban or VKAs between 2013 and 2015 were included...
March 16, 2017: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/28300864/whole-exome-sequencing-in-the-framingham-heart-study-identifies-rare-variation-in-hyal2-that-influences-platelet-aggregation
#13
John D Eicher, Ming-Huei Chen, Achilleas N Pitsillides, Honghuang Lin, Narayanan Veeraraghavan, Jennifer A Brody, Ginger A Metcalf, Donna M Muzny, Richard A Gibbs, Diane M Becker, Lewis C Becker, Nauder Faraday, Rasika A Mathias, Lisa R Yanek, Eric Boerwinkle, L Adrienne Cupples, Andrew D Johnson
Inhibition of platelet reactivity is a common therapeutic strategy in secondary prevention of cardiovascular disease. Genetic and environmental factors influence inter-individual variation in platelet reactivity. Identifying genes that contribute to platelet reactivity can reveal new biological mechanisms and possible therapeutic targets. Here, we examined rare coding variation to identify genes associated with platelet reactivity in a population-based cohort. To do so, we performed whole exome sequencing in the Framingham Heart Study and conducted single variant and gene-based association tests against platelet reactivity to collagen, adenosine diphosphate (ADP), and epinephrine agonists in up to 1,211 individuals...
March 16, 2017: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/28276572/joannsin-a-novel-kunitz-type-fxa-inhibitor-from-the-venom-of-prospirobolus-joannsi
#14
Ning Luan, Chunling Zhou, Pengpeng Li, Rose Ombati, Xiuwen Yan, Guoxiang Mo, Mingqiang Rong, Ren Lai, Zilei Duan, Ruiqiang Zheng
The repugnatorial glands of millipedes release various defensive chemical secretions. Although varieties of such defensive secretions have been studied, none of them is protein or peptide. Herein, a novel factor Xa (FXa) inhibitor named joannsin was identified and characterised from repugnatorial glands of Prospirobolus joannsi. Joannsin is composed of 72 amino acid residues including six cysteines, which form three intra-molecular disulfide bridges. It is a member of Kunitz-type protease inhibitor family, members of which are also found in the secretory glands of other arthropods...
March 9, 2017: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/28276571/predictors-of-active-cancer-thromboembolic-outcomes-riete-experience-of-the-khorana-score-in-cancer-associated-thrombosis
#15
Alfonso J Tafur, Joseph A Caprini, Lauren Cote, Javier Trujillo-Santos, Jorge Del Toro, Fernando Garcia-Bragado, Carles Tolosa, Giovanni Barillari, Adriana Visona, Manuel Monreal
Even though the Khorana risk score (KRS) has been validated to predict against the development of VTE among patients with cancer, it has a low positive predictive value. It is also unknown whether the score predicts outcomes in patients with cancer with established VTE. We selected a cohort of patients with active cancer from the RIETE (Registro Informatizado Enfermedad TromboEmbolica) registry to assess the prognostic value of the KRS at inception in predicting the likelihood of VTE recurrences, major bleeding and mortality during the course of anticoagulant therapy...
March 9, 2017: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/28276570/the-role-of-rna-uptake-in-platelet-heterogeneity
#16
Lauren Clancy, Lea M Beaulieu, Kahraman Tanriverdi, Jane E Freedman
The role of platelets in regulating vascular homeostasis has expanded beyond mediation of haemostasis and thrombosis. The discovery of platelet RNA and the presence of subpopulations of platelets containing varying amounts of RNA suggest a role for platelet transcripts in vascular function. As the RNA in anucleated platelets is biologically functional and may transfer to other vascular cells, we hypothesised that platelet RNA diminishes over the lifespan of the platelet with diminishing platelet size due to horizontal cellular transfer...
March 9, 2017: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/28276569/ccr5-cd8-t-cell-levels-and-monocyte-activation-precede-the-onset-of-acute-coronary-syndrome-in-hiv-infected-patients-on-antiretroviral-therapy
#17
Laura Tarancon-Diez, Rebeca S De Pablo-Bernal, Ana I Álvarez-Rios, Isaac Rosado-Sánchez, Beatriz Dominguez-Molina, Miguel Genebat, Yolanda M Pacheco, José Luis Jiménez, M Ángeles Muñoz-Fernández, Ezequiel Ruiz-Mateos, Manuel Leal
Acute coronary syndrome (ACS) is nowadays one of the leading causes of morbid-mortality in HIV-infected population, but innate and adaptive immune mechanisms preceding this event are unknown. In this work we comprehensively and longitudinally observed, by multiparametric flow cytometry and following a case-control design, increased CCR5(+)CD8(+) T-cells levels and monocytes expressing activation and adhesion markers in HIV-infected patients who are going to suffer ACS. In addition, we found direct associations between activated CD8(+) T-cells and myeloid cells that were only statistically significant in the group of patients with ACS and in the follow up time point just before the ACS...
March 9, 2017: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/28276568/predicting-bleeding-risk-after-coronary-surgery-let-s-focus-on-modifiable-risk-factors-and-simple-practical-decision-making
#18
Vanessa Roldán, Francisco Marín
No abstract text is available yet for this article.
March 9, 2017: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/28276567/patient-values-and-preferences-for-antithrombotic-therapy-in-atrial-fibrillation-a-narrative-systematic-review
#19
Peter S Loewen, Angela Tianshu Ji, Anita Kapanen, Alison McClean
Guidelines recommend that patients' values and preferences should be considered when selecting stroke prevention therapy for atrial fibrillation (SPAF). However, doing so is difficult, and tools to assist clinicians are sparse. We performed a narrative systematic review to provide clinicians with insights into the values and preferences of AF patients for SPAF antithrombotic therapy. Narrative systematic review of published literature from database inception. RESEARCH QUESTIONS: 1) What are patients' AF and SPAF therapy values and preferences? 2) How are SPAF therapy values and preferences affected by patient factors? 3) How does conveying risk information affect SPAF therapy preferences? and 4) What is known about patient values and preferences regarding novel oral anticoagulants (NOACs) for SPAF? Twenty-five studies were included...
March 9, 2017: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/28276566/external-validation-of-the-vte-bleed-score-for-predicting-major-bleeding-in-stable-anticoagulated-patients-with-venous-thromboembolism
#20
Frederikus A Klok, Stefano Barco, Stavros V Konstantinides
One of the main determinants of establishing the optimal treatment duration of patients with venous thromboembolism (VTE) is the risk of major bleeding during long-term anticoagulant therapy. The 6-variable VTE-BLEED score was recently developed to enable estimation of this bleeding risk. This study aimed at externally validating VTE-BLEED. This was a post-hoc study of the randomised, double-blind, double-dummy, Hokusai-VTE study that compared edoxaban versus warfarin for treatment of VTE. VTE-BLEED was calculated in all 8,240 study patients...
March 9, 2017: Thrombosis and Haemostasis
journal
journal
26757
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"